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ABSTRACT 
Background: Beta blocker therapy is indicated in all patients with heart failure with reduced ejection 
fraction (HFrEF) as per current guidelines. The relative benefit of carvedilol to metoprolol succinate 
remains unknown. This study aimed to compare survival benefit of carvedilol to metoprolol succinate. 
Methods: The VA’s databases were queried to identify 114,745 patients diagnosed with HFrEF from 
2007 to 2015 who were prescribed carvedilol and metoprolol succinate. The study estimated the 
survival probability and hazard ratio by comparing the carvedilol and metoprolol patients using 
propensity score matching with replacement techniques on observed covariates. Sub-group analyses 
were performed separately for men, women, elderly, duration of therapy of more than 3 months, and 
diabetic patients. 
Results:  A total of 43,941 metoprolol patients were matched with as many carvedilol patients. The 
adjusted hazard ratio of mortality for metoprolol succinate compared to carvedilol was 1.069 (95% CI: 
1.046-1.092, p value:<0.001). At six years, the survival probability was higher in the carvedilol group 
compared to the metoprolol succinate group (55.6% vs 49.2%, p value <0.001). The sub-group analyses 
show that the results hold true separately for male, over or under 65 years old, therapy duration more 
than three months and non-diabetic patients. 
Conclusion: Patients with HFrEF taking carvedilol had improved survival as compared to metoprolol 
succinate. The data supports the need for furthering testing to determine optimal choice of beta 
blockers in patients with heart failure with reduced ejection fraction. 
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ABBREVIATIONS 
ACC: American College of Cardiology 
AHA: American Heart Association 
HF: Heart failure 
COPD: Chronic obstructive pulmonary disease 
HR: Hazard ratio 
HbA1c- Glycosylated hemoglobin A1c 
ICD-9: International Classification of Diseases, Ninth Revision 
ICD: Implantable cardioverter defibrillator 
Afib: Atrial fibrillation  
CKD: Chronic kidney disease 
PAD: Peripheral artery disease 
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BACKGROUND 
Beta blocker therapy is indicated in the treatment of all patients with heart failure with reduced ejection 
fraction (HFrEF) as per current guidelines1-3.  Overexpression of beta-1 and beta-24 leads to 
cardiomyopathy and increased fibrosis and cardiomyocyte apoptosis suggesting their role in heart 
failure.5 Catecholamines trigger alpha-1 and beta-2 receptors, causing vasoconstriction and 
vasodilatation, with vasodilation being impaired in heart failure.6-8  The three trial-proven beta blockers 
in the United States for such patients are carvedilol, metoprolol succinate, and bisoprolol. Of these, 
carvedilol and metoprolol succinate are most commonly used in the United States. Although studies 
have shown that both beta-blockers are beneficial in reducing mortality and morbidity in HFrEF, there 
are few data on comparative effectiveness of these medications.  
Carvedilol has beta-1, beta-2 and alpha receptor blocking properties, unlike metoprolol succinate which 
blocks only the beta-1 receptor.1, 9  The relative benefits of non-selective beta-blockade over 
cardioselective beta-1 blocker therapy are debatable.10 The differential effects of carvedilol and 
metoprolol on hemodynamics and left ventricular function have been previously described.11, 12 In the 
prospective, randomized trial, COMET (Carvedilol or Metoprolol European Trial), carvedilol decreased 
mortality compared to metoprolol tartrate.13 However, this trial was difficult to interpret due to the 
suggestion of under-dosing with the metoprolol tartrate formulation. The succinate formulation of 
metoprolol and not tartrate was studied and approved for heart failure.   
In this study, a retrospective analysis was conducted on the comparative survival benefits of carvedilol 
and metoprolol succinate on a large national database of patients with HFrEF.  
METHODS  
Study Population 
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The Veteran’s Affairs (VA) administration provides care for approximately 9 million veterans and their 
families in the United States.14 Patients with HFrEF were identified using International Classification of 
Diseases 9th Revision (ICD-9) codes. During the period of analysis carvedilol and metoprolol succinate 
were restricted by the VA pharmacy exclusively for patients with a diagnosis of HF with an ejection 
fraction less than 40% in the VA system. Pharmacy consultation is required for a provider to prescribe 
either medication. The VA’s Corporate Data Warehouse (CDW) inpatient, outpatient, and pharmacy 
databases were queried to identify patients diagnosed with heart failure either as an inpatient or an 
outpatient from January 1st 2007 to January 27th 2015 using the VINCI platform. The included patients 
were required to have filled an outpatient prescription for either carvedilol or metoprolol succinate.  
The initial start of beta blocker was the recorded date of the first time the medication was filled at a VA 
pharmacy.  
The patients who did not refill the medication through a VA outpatient pharmacy and those who did not 
take the medication for more than 30 days were excluded. Additionally, the patients who had crossed 
over to a different beta blocker at any time were excluded. Follow-up duration was defined as the time 
from the first VA outpatient pharmacy fill date to death or to the end of the study. Beta blocker status 
prior to the start date of the study was not able to be reviewed. 
Our initial sample had 165,159 patients who were treated with either carvedilol or metoprolol succinate. 
Then observations (excluded subjects) with missing or inconsistent values in sex, treatment start date, 
duration of treatment, date of birth, and death were removed. Also, the patients who died within 30 
days of treatment were removed to prevent other unobserved confounding variables. The observations 
with the treatment start date outside of our study period and observations with inconsistent coding in 
diabetes (i.e., diabetic patients without a documented HbA1c ≥ 6.5%) were omitted. A high dosage of 
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beta blocker (BB) variable was identified as average daily dose ≥25 mg for carvedilol and ≥100 mg for 
metoprolol succinate.15 
Comorbidities and Outcomes 
All the patients’ comorbidities were based on outpatient or inpatient ICD-9 codes. Mortality data was 
obtained through the VA’s death registry. Heart rates were obtained both from outpatient and inpatient 
settings. Race data was self-reported and was retrieved through the VA databases.  Implantable 
cardioverter-defibrillator (ICD) implantation was defined by Current Procedural Terminology (CPT) codes 
and ICD-9 codes.  Heart rates were obtained both from outpatient and inpatient settings. 
Statistical Analysis 
Using Student’s t-Test, the means of all variables across both treatment groups were compared. To 
account for the significant differences in baseline characteristics, comorbidities, and medications 
between carvedilol and metoprolol, a propensity score matching method to balance the observable 
covariates was used. Propensity score matching with replacement ensures patients in our sample were 
comparable on their key observable characteristics to test the differences in mortality among 
metoprolol and carvedilol patients. Failing to account for matching could lead to significant bias due to 
unobserved confounders.16  The propensity scores were computed by running a logistic regression 
model, with metoprolol succinate (treated group) as dependent variable, patient characteristics such as 
age, sex, high dose of BB, comorbidities (presence of an ICD, afib, CAD, kidney disease, COPD, cerebral 
vascular accident, cirrhosis, deep vein thrombosis, hypertension, obstructive sleep apnea, peripheral 
arterial disease, pulmonary embolism, smoking status, and diabetes mellitus), and medications (loop 
diuretic, P2Y12 inhibitor, elperenone/spironolactone, anticoagulants, ACE inhibitor or ARB, calcium 
channel blocker, statin, digoxin, nitrate, hydralazine, and aspirin) as control variables. With the 
propensity scores, a 1:1 matching with replacement was performed. The balance of the matched data 
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between carvedilol and metoprolol groups was tested using paired t-test and a p value >0.01 for most 
covariates was considered as an acceptable balance. Among the matched sample, Cox proportional 
hazard regression models were applied to compare the mortality differences between the two groups. 
To account for potential misspecification of the model (i.e., error term in the model being not identically 
distributed), the proportional hazard model with robust standard errors was used. 
Several subgroup analyses for different groups were tested for on the matched sample to evaluate the 
mortality differences between carvedilol and metoprolol. These sub-groups include women, men, 
African-Americans, over 65 years old, under 65 years old, individuals with therapy duration more than 
three months, and diabetic vs. non-diabetic sub-groups. For each sub-groups, the hazard ratio of 
carvedilol versus metoprolol succinate was determined.  For robustness tests, the main results were 
tested with a Poisson model.  
All data analyses were performed using STATA 15.0 (StataCorp LP, Texas, USA).  
RESULTS  
The original query contained 881,804 veterans, and 165,159 veterans with diagnosis of HFrEF remained 
after the removal of patients without continuous carvedilol or metoprolol succinate use. After removing 
veterans with missing information on baseline characteristics or outcomes, the study group was 
comprised of 114,745 HF patients treated with either carvedilol (61.71%) or metoprolol succinate 
(38.29%). Before matching, the average follow-up time was 3.46±0.02 years for carvedilol group and 
3.44±0.02 years for metoprolol group. The average heart rate for carvedilol group was 74.6 bpm and for 
metoprolol group was 75.1 bpm prior to matching.  
Table 1 shows the comparison of baseline characteristics of metoprolol and carvedilol groups before and 
after the matching. Prior to matching, we find that most of the variables were significantly different 
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from each other. Metoprolol patients were 2.6 years older than carvedilol patients, and more likely to 
have atrial fibrillation, COPD, hypertension, and peripheral arterial disease than carvedilol patients. 
Further, they were less likely to have kidney disease, and less likely to smoke than carvedilol patients 
before matching.  
Using 1:1 propensity score matching technique with replacement, 43,941 patients treated with 
carvedilol were matched with 43,941 patients treated with metoprolol succinate. After matching, the 
average follow-up time was 3.46±0.02 years for carvedilol group and 3.44±0.02 years for metoprolol 
group. After matching, the average heart rate for carvedilol group was 74.4 bpm and for metoprolol 
group was 75.1 bpm. The average daily dose of carvedilol was 17.73 mg and the average daily dose of 
metoprolol was 103.14 mg. The last three columns of Table 1 show the comparison of means of 
covariates between the carvedilol and metoprolol sample post matching. The baseline characteristics 
were mostly balanced and there were no significant differences in most of the covariates [26 out of 28 
covariates were insignificant at 1% level] between the two groups. Figure 1 demonstrates the survival 
curve of carvedilol and metoprolol succinate for the matched sample. At six years, the survival 
probability was higher in the carvedilol group compared to the metoprolol group (0.556 vs 0.492, p 
value <0.001).  
Table 2 presents the Cox Proportional Hazard results of treatment using metoprolol succinate relative to 
carvedilol on patients after matching observations based on patient’s age, sex, comorbidities, and 
medications. Model C presents the Cox proportional hazard model results adjusting for patient’s age, 
sex, high BB dose, comorbidities, and medications. The results after propensity score matching show 
that the unadjusted HR was 1.100 (95% CI: 1.077-1.123, p value:<0.01) and adjusted HR was 1.069 (95% 
CI: 1.046-1.092, p- value:<0.01). Figure 2 shows the Cox proportional Hazard estimates across different 
sub-groups on the matched sample (such as sex, race, age group, therapy duration, and presence of 
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diabetes).  The mortality adjusted for baseline characteristics were higher than 1 for all the sub-groups 
except for women likely due to the low number of women in this study and diabetes patients. The main 
results were tested with a Poisson model and consistent results of hazard ratio (HR: 1.125, 95% CI: 
1.101-1.148, p value:<0.01) were found. 
DISCUSSION 
To our knowledge, this is the largest study comparing carvedilol to metoprolol succinate for mortality in 
patients with HFrEF and includes contemporary patients in a setting outside of the confines of a 
randomized trial. The study demonstrated that overall, carvedilol use is associated with lower all-cause 
mortality compared to metoprolol succinate when matched for comorbidities. For the entire matched 
sample, the mortality rate of metoprolol was 43.1%, whereas the mortality rate of carvedilol was 38.2% 
(p value <0.01).  From Figure 1, the mortality rates of using carvedilol (our control group) at 4 years post-
treatment was 0.25. From Table 2, we obtain the hazard ratio after adjusting for covariates comparing 
the metoprolol group (our treatment group) with the carvedilol group as 1.069. Therefore, for every 44 
patients treated with metoprolol succinate for four years (after adjusting for covariates) one death will 
occur beyond those that would have happened when carvedilol is used.   
The relative benefits of carvedilol compared to metoprolol succinate remains a matter of debate. It has 
been hypothesized that the superiority of carvedilol may be attributed to pleiotropic effects on 
endothelial function,17 metabolic,18 antioxidant,19, 20 and antiarrhythmic actions.20 The COMET trial, 
which remains the only large trial comparing carvedilol with metoprolol, showed that carvedilol was 
superior to metoprolol tartrate in patients with HF.13  However, the trial had a limitation in that the 
heart rates between the two groups were not comparable for the first 16 months thus casting a doubt 
about direct comparison between the two treatment groups. Additionally, shorter acting metoprolol 
tartrate was studied in COMET while the mortality benefit of beta blockers in MERIT-HF was 
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demonstrated with metoprolol succinate formation which was exclusively analyzed in our study.21 The 
key differences in pharmacokinetics of metoprolol tartrate to the longer acting succinate are 
characterized by greater peak-to-through fluctuations compared to metoprolol succinate. Metoprolol 
tartrate reaches high plasma levels 2-3 hours after ingestions, then concentrations and beta blockade 
fall to lower levels. The sympathetic inhibition reached in the first hours after ingestion of tartrate may 
limit the increase in the drug doses leading to insufficient B-1 blockade in the subsequent hours.5 The 
average heart rates in COMET trial were 67.7 and 69.3 bpm compared to the averages in this study of 
74.4 and 75.1 bpm. This may represent that outside of randomized control trials, beta blockers are often 
under-dosed. A recent meta-analysis also suggested the survival benefit of carvedilol to metoprolol 
tartrate is lost when compared to metoprolol succinate.22 Hence, our comparison of carvedilol to 
metoprolol succinate can help to fill this gap in the literature.  
Since COMET, several smaller database studies have reported on the outcomes in HF patients comparing 
carvedilol with metoprolol succinate. Our results contrast with a prior smaller study of 3716 subjects 
done by Shore and co-workers23 in which patients with ischemic HF did better on metoprolol succinate 
while those with nonischemic HF did better on carvedilol. More recently, Fröhlich and colleagues found 
in a study of 4,016 Norwegian and German outpatients, that there was no difference in mortality in 
patients taking carvedilol or metoprolol succinate after adjusting for variables and especially medication 
doses.24 Our study included a larger cohort of patients with a substantially longer follow-up period 
compared to these smaller studies. Similarly, Pasternak and co-workers reported on approximately 
11,500 patients from the Danish registry in patients with stable heart failure and showed no difference 
between the two medications either in the overall cohort or among subgroups.25 In contrast, most of 
our subgroups also showed better survival with carvedilol. A recent meta-analysis of four prospective 
and six cohort studies showed no difference between the two medications in terms of mortality in the 
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overall analysis.22  Analyses of randomized prospective trials showed superiority of carvedilol which is 
mainly driven by the results of COMET.22 
Contrary to our expectations, diabetics fared better with metoprolol succinate. This may suggest that 
the beneficial effect of carvedilol on insulin resistance does not translate into clinical benefit. Further 
studies are required to understand the potential reasons for superiority of metoprolol succinate among 
diabetes with HF.  
The strengths of our study are the large sample size, nationwide distribution, and a long duration of 
follow-up. Besides the critical elements, the two medications were clinically well matched.  
Study Limitations 
Our study has all the limitations of a retrospective analysis. While our data did not include most 
cardiovascular endpoints, we feel all-cause mortality reduction was the most important endpoint.  
Although we adjusted for baseline characteristics, not all confounders can be adjusted in a retrospective 
study. Thus, this study is subject to residual confounding. For instance, we were not able to take into 
account factors that influence the choice of beta-blockers in HFrEF patients such as patient’s tolerance 
to beta-blocker including blood pressure or clinician's preference. In addition, we were unable to 
determine the heart failure functional class or severity. Being a VA study, women were 
underrepresented.  Although all subjects had assumed ejection fraction ≤ 40%, given VA restrictions on 
these medications along with ICD9 diagnosis of HFrEF and similar rates of ICD implantation, individual 
ejection fraction are not obtained reliably from the database so validation of this assumption was not 
possible. Estimate of diastolic function could also not be ascertained. In addition, the exact etiology of 
the reduced ejection fraction was not possible.  
Conclusion 
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Our study demonstrated that overall patients with HFrEF taking carvedilol had improved survival as 
compared to metoprolol succinate. The data supports the need for furthering testing to determine 
optimal choice of beta blockers in patients with heart failure with reduced ejection fraction. 
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Clinical Perspectives: 
This study demonstrates an important question for patient care, because there are multiple beta 
blockers available to treat heart failure. Our data suggest that carvedilol may be considered as first-line 
therapy in clinical decision making.  
Translational Outlook: 
These data support the need for definitive randomized controlled trial examining outcomes and 
response between carvedilol and metoprolol succinate.  
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Figure 1: Kaplan Meier Survival Estimates: Carvedilol versus Metoprolol Succinate on Matched Sample 
 
 
Note: Matched on age, sex, high dose, medications and comorbidities 
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Figure 2  Cox proportional Hazard Estimates across Different Sub-groups on the Matched Sample  
 
Note: Matched on age, sex, high dose, medications and comorbidities 
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Table 1: Comparison of Baseline Characteristics of Metoprolol vs. Carvedilol Group Before and After 
Matching 
  Pre-matching Post-Matching 
Variables Carvedilol Metoprolol p value Carvedilol Metoprolol p value 
Total 70,804 43,941   43,941 43,941   
Age, years 
67.382 ± SD 
11.087 
69.985 ± SD 
11.018 <0.001 
70.024 ± SD 
11.131 
69.985 ± SD 
11.018 0.602 
Women 0.018 0.018 0.523 0.018 0.018 0.508 
High BB 
Dose 0.427 0.585 <0.001 0.578 0.585 0.047 
ICD 0.238 0.217 <0.001 0.22 0.217 0.340 
Atrial 
fibrillation 0.304 0.419 <0.001 0.433 0.419 <0.001 
Coronary 
artery 
disease 0.64 0.65 <0.001 0.653 0.65 0.305 
Chronic 
kidney 
disease 0.389 0.362 <0.001 0.362 0.362 0.966 
COPD 0.305 0.331 <0.001 0.333 0.331 0.505 
CVA 0.12 0.117 0.141 0.113 0.117 0.032 
Cirrhosis 0.022 0.021 0.194 0.019 0.021 0.238 
DVT 0.047 0.051 0.004 0.05 0.051 0.558 
End stage 
renal 
disease 0.067 0.055 <0.001 0.054 0.055 0.407 
Hypertensio
n 0.628 0.705 <0.001 0.702 0.705 0.408 
OSA 0.171 0.17 0.481 0.17 0.17 0.829 
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Peripheral 
arterial 
disease 0.235 0.249 <0.001 0.252 0.249 0.354 
Pulmonary 
embolism 
0.026 0.029 0.004 0.026 0.029 0.040 
Smoking 0.255 0.239 <0.001 0.233 0.239 0.056 
Diabetes 
Mellitus 0.572 0.485 <0.001 0.489 0.485 0.160 
Loop 
Diuretic 0.802 0.761 <0.001 0.761 0.761 0.962 
P2Y12 
inhibitor 0.439 0.379 <0.001 0.382 0.379 0.355 
Eplerenone
/Spironolact
one 0.359 0.268 <0.001 0.268 0.268 0.951 
Anticoagula
nt 0.313 0.392 <0.001 0.396 0.392 0.288 
ACE 
inhibitor/AR
B 0.944 0.916 <0.001 0.912 0.916 0.040 
Calcium 
Channel 
Blocker 0.457 0.433 <0.001 0.432 0.433 0.728 
Statin 0.9 0.89 <0.001 0.888 0.89 0.512 
Digoxin 0.237 0.254 <0.001 0.253 0.254 0.692 
Nitrate 0.341 0.339 0.425 0.345 0.339 0.060 
Hydralazine 0.198 0.135 <0.001 0.136 0.135 0.730 
Aspirin 0.605 0.614 0.001 0.614 0.614 0.956 
Average 
Heart Rate 
74.595 ± SD 
8.965 
75.132 ± SD 
9.293 <0.001 
74.348 ± SD 
8.748 
75.132 ± SD 
9.293 <0.001 
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Table 2: Cox Proportional Hazard Ratio of Metoprolol vs. Carvedilol Group Before and After Matching 
MODELS Metoprolol as Treatment Relative to Carvedilol 
Matched Sample 
N=87,882        
Model A Unadjusted 
Hazard Ratio 1.100 
p value <0.001 
95% CI 1.077-1.123 
Model B 
Adjusted with Patient 
Characteristics, high BB 
dose and Comorbidities  
Hazard Ratio 1.073 
p value <0.001 
95% CI 1.051-1.096 
Model C (Preferred Cox 
model) 
Adjusted with Patient 
Characteristics, high BB 
dose, Comorbidities, 
and Medications 
Hazard Ratio 1.069 
p value <0.001 
95% CI 1.046-1.092 
Note: Matched sample is based on age, sex, high BB dose, comorbidities and medications. 
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